STI Stock Trade Intelligence
ILA

ISLAND PHARMACEUTICALS LIMITED

Health Care · ASX:ILA
$0.3770
▲ +1.89%
Market cap
$112M
Turnover
$70,455
Last price
$0.3770
Day change
+1.89%
Announcements
21
Range, past year
Open 0.370 · Low 0.130 · Now 0.377 · High 0.630
Open ILA in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

ILA momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-10-13.
Momentum quality
36/100
Wyckoff phase
Downtrend14d
Trend stage
Breakdown
1 Day
+1.9%
1 Week
+3.3%
1 Month
-12.3%
1 Year
-5.8%
RSI
41
Avg daily range
3.9%

ISLAND PHARMACEUTICALS LIMITED scores 36 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.

On the Wyckoff cycle it sits in Downtrend, where it has been for 14 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -25.5%
  • Thin liquidity
  • Risk rating: Very High
  • Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

ILA announcements

Recent price-sensitive releases.
  • 2026-10-02 Galidesivir GMP manufacturing commences Progress Report
  • 2026-08-31 Pivotal Marburg data secured for Galidesivir FDA pathway Progress Report
  • 2026-08-26 Preliminary Final Report Preliminary Final Report
  • 2026-08-21 Island boosts Galidesivir supply as Ebola surges Progress Report
  • 2026-07-30 Quarterly Appendix 4C and Activities Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
  • 2026-07-13 Texas Biomed SOW accelerates pivotal FDA pathway
  • 2026-07-08 Investor Presentation - Ebola Clinical Program
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.